Key facts
- It has raised $1.1M across 2 recorded rounds; the latest was Seed Round ($300K) in May 2025.
- Epoch Biotech has filed 3 Form Ds with the SEC since 2023, most recently Jun 2025 ($140K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Epoch Biotech
Funding rounds
2 roundsAbout Epoch Biotech
Developer of a healthcare technology platform intended to offer patient-inspired treatments for alzheimer's disease. The company's platform provides new therapies and identifies the underlying molecular mechanisms of resilience with inherited disease, enabling patients to get rid of neurological disorders.
- Sector
- Healthcare
- HQ
- Dover, MA, United States
- Founded
- 2022
- Website
- epochbiotech.com/
- Ownership
- Privately Held (backing)
Epoch Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epoch Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epoch Biotech in its N-PORT filings yet. We sweep new filings monthly.